Thursday 29 December 2016

Global Analysis for Surgical Shadowless Lamps Market Trends & Forecast 2023

Surgical shadowless is a technology used for operating theater lighting systems. These are generally lamps that demand less shadows and better clarity to the healthcare professionals while performing surgeries. Surgical shadowless lamps are generally used by surgeons and dentists while performing neurosurgery, endoscopic surgeries, dental surgeries, optical surgeries and others. Better surgical lighting enables doctors to perform superior and successful surgeries. In addition, surgical shadowless lamps are also used in outpatient and inpatient operating rooms. 


The surgical shadowless lamps can be classified according to technology into two types:

By Technology:
  • Halogen based surgical shadowless lamps.
  • Light emitting diode (LED) based surgical shadowless lamps.
Halogen based surgical shadowless lamps is an old technology which is currently being replaced by LED based surgical shadowless lamps. Halogen lamps cause environmental pollution and produces large amount of heat that leads to additional difficulty for the surgeon while performing the surgical procedures. On the other hand, LED based surgical lamps produce cold light, low temperature, high color rendering and long life term. Thus, owing to the above mentioned advantages LED based surgical lamps are preferred by the healthcare professionals over halogen based surgical shadowless lamps. The surgical shadowless lamps can also be classified based on portability as:

By Portability
  • Fixed ceiling surgical lamps
  • Portable surgical lamps
The fixed ceiling surgical lamps are most common among the hospitals and ambulatory surgical centers. Some of the outpatient surgeries are performed using the portable surgical lamps which demands portability. The trend of surgical shadowless lamps is shifting towards more advanced LED lamps due to their affordability, no heat radiation and better color rendering qualities. Thus, all the above mentioned factors support the growth of surgical shadowless lamps market during the forecast period from 2014 to 2020.

In 2013, North America dominated the global surgical shadowless lamps market followed by Europe. The dominance of this region was majorly due to better healthcare infrastructure that propels the demand for surgical shadowless lamps in North America. Increasing number of inpatient and outpatient surgeries in North America also drive the growth of this market segment in the region. In addition, rising preference for LED based surgical shadowless lamps is also one of the prime factors supporting the uptake of these lamps in the region. European region comprises countries such as the U.K., Germany, France, Italy and Spain. Factors such as established healthcare infrastructure and growing healthcare awareness accentuate the growth of surgical shadowless lamps market in the European region. Furthermore, Asia Pacific and Latin America are the most lucrative markets for surgical shadowless lamps market during the forecast period from 2014 to 2020. The growth of this region was majorly due to developing healthcare infrastructure and increasing number of minimally invasive surgeries performed in the region. India, Brazil and China are the most attractive countries in Asia Pacific market for surgical shadowless lamps.

The market for surgical shadowless lamps is diversified, as products are designed as per the requirement of the operating room. Some of the key players having presence in the global surgical shadowless lamps market are Getinge USA, Inc., Shangdong Mingtai Medical Devices Co., Ltd., Welch Allyn, Skytron, Derungs Licht AG, Integra Life Sciences, A-Dec, Inc., Sansi Technologies, Inc., United Surgical Industries, etc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse Full Research Report on Surgical Shadowless Lamps Market:
http://www.transparencymarketresearch.com/surgical-shadowless-lamps-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Care Management Solutions Market to Witness Robust Growth thanks to Flourishing Medical Tourism Industry

A new market intelligence study by Transparency Market Research provides an in-depth overview of the care management solutions market across the globe. The research study, titled “Care Management Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024,” offers a comprehensive analysis, emphasizing on the key growth drivers, opportunities, and current trends in the market. The past performance and forecast statistics of the global care management solutions market have also been highlighted in the research report.


A care management solution initially accesses patient data and determines their healthcare needs. After the assessment, the care management software offers healthcare plans for the patients and further provides a list of diverse coordinators on the same page, thus allowing different departments to execute their tasks efficiently. The global market for care management solutions is expected to witness the emergence of several players, many of whom will be large companies with diversified business interests.

The growing geriatric population, rising incidences of chronic diseases, and booming medical tourism industry are some of the prominent factors anticipated to augment the growth of the worldwide care management solutions market in the next few years. In addition, the introduction of IT in healthcare services and the rising demand for big data are expected to bolster the global market in the coming years. Furthermore, initiatives taken by healthcare providers to promote patient-centric care and favorable government regulations are estimated to boost the demand for care management solutions in the forecast period.

On the flip side, the reluctance of healthcare providers to adopt care management solutions and the high capital requirement for supporting infrastructure are some of the primary factors estimated to dampen the growth of the global care management solutions market in the near future. Moreover, inadequate patient engagement, lack of interoperability, and concerns related to data security are expected to restrict the growth of the overall market throughout the forecast period. Nevertheless, the growing adoption of cloud-based models, technological advancements, and rising consumer awareness regarding the benefits of care management solutions are projected to encourage the growth of the market in the coming years.

Furthermore, the research study analyzes the product segmentation and geographical segmentation of the global market for care management solutions to determine the leading segments and growth prospects. The demand, consumption, supply, share, and growth rate of each segment have been discussed in the scope of the research report. Allscripts Healthcare Solutions, Inc., TriZetto Corporation, HealthSmart Holdings, Inc., and EXL Healthcare are some of the leading players operating in the care management solutions market across the globe. The market is lucrative in nature, owing to which several new players are estimated to enter the market throughout the forecast period.

Browse Full Research Report on Care Management Solutions Market:http://www.transparencymarketresearch.com/care-management-solutions-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Tele-intensive Care Services Market Key Trends & Forecast 2024

A new market research report by Transparency Market Research, titled “Tele-intensive Care Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024,” provides a comprehensive understanding of the market. The report is compiled by utilizing both primary and secondary research and presents key insights into the prime market dynamics. Some of these dynamics are drivers, opportunities, challenges, and inhibitors impacting the development of the market from 2016 to 2024. The chief trends prevalent in the global tele-intensive care services market have also been presented. A review on the macro and micro factors benefitting the established players and the emerging players also forms an integral part of this report. 


The first section of the study throws light on the significance of tele-intensive care services. The implementation of tele-intensive care services aid medical practitioners in monitoring any significant signs in patients. The employment of these services also impede any issues that may otherwise take place owing to hospital-settings. 

As stated in the report, the rate of mortality is approximately 10% and may even touch up to 28% within intensive care units (ICU) settings, globally. Thus, a number of hospital managers and healthcare professionals have been actively working on introducing various tele-intensive care services in order to lower the count of ICU deaths. Tele-intensive care units have aided in lowering the duration of stay in ICUs and keep the errors that may occur in providing medications under check. All these benefits will raise the demand for tele-intensive care services, thus bolstering market growth, as per this study.

The report further opines that the increasing implementation of tele-intensive care services globally will also boost the growth of the market. In addition, the time and cost saving benefits related with the utilization of intensive care services will positively impact the development of the overall market. Furthermore, the growing confidence and interest amongst healthcare professionals in remote patient monitoring will drive the growth of this market.

On the basis of product, the report categorizes the tele-intensive care service market into software and hardware. Of these, hardware components are sub-segmented into therapeutic devices, computer systems, communication lines, physiological monitors, video feeds, and display panels. In terms of type, the market is categorized into intensivist, co-managed, open, and open with consultants. Geographically, the report segments the market into Asia Pacific, North America, Europe, and Rest of the World (RoW). 

As stated in this report, the prime players in the global tele-intensive care services market are Advanced ICU care, UPMC Italy, inTouch health, INTELEICU, INOVA, Philips, and iMDsoft, among others.

Browse Full Research Report on Tele-intensive Care Services Market:
http://www.transparencymarketresearch.com/tele-intensive-care-unit-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Super Resolution Microscopy Market by Product, Application & End Users - 2023

A new market research report by Transparency Market Research presents a comprehensive analysis of the global market for super resolution microscopes. The research report, titled “Super Resolution Microscopes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” covers the market’s overview, current market trends, market drivers and restraints, product segmentation, major geographical segments, and competitive analysis of the market. The research study further provides the historical data and forecast figures of the global super resolution microscopes market with the help of infographics, charts, and tables. The study also includes valued inputs by industry experts to assist the new as well as existing players in formulating their business policies effectively.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4673

The research report has segmented the global market for super resolution microscopes on the basis of technology into stochastic function resolution technique, deterministic functional resolution technique, combination resolution techniques, and true super resolution technique. The market share and market size estimates are further discussed in the scope of the research report. 

Furthermore, on the basis of application, the global market for super resolution microscopes has been classified into nanotechnology, geo-material research, life sciences, material sciences, research laboratories, and semiconductor manufacturing. Among these, in terms of volume, the life sciences segment accounts for the largest share in the overall super resolution microscopes market. The life sciences segment is further sub-categorized into biopharmaceutical companies, science universities, and forensic laboratories. On the other hand, in terms of value, the nanotechnology and material sciences segments are considered among the largest segment in the global market.

The research report on the global market for super resolution microscopes has been divided on the basis of geography into the Middle East and Africa, North America, Latin America, Asia Pacific, and Europe. The Asia Pacific and North America markets are considered as the most promising regions in the global market. The demand for super resolution microscopes is expected to grow substantially, exhibiting a significant growth rate in the forecast period. China, Australia, and Japan are the major markets in the Asia Pacific region. The super resolution microscope market in the Rest of the World is anticipated to grow at a stable rate, compared to other major economies around the world.

The research study further talks about the competitive landscape of the global market for super resolution microscopes, focusing on the company profiles of major players and their contact information, financial overview, business policies, SWOT analysis, and recent developments if any. Some of the major players operating in the global market for super resolution microscopes are Nikon Corporation, Olympus Inc., Carl Zeiss AG, Hitachi High Tech Corporation, GE LifeSciences, JEOL Ltd, Bruker Corporation, FEI Company, and Leica Microsystems.

Browse Full Research Report on Super Resolution Microscopes Market:
http://www.transparencymarketresearch.com/super-resolution-microscopes-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

In-vitro Cancer Diagnostics Market Analysis and Forecasts, By Product Type 2024

Global In-vitro Cancer Diagnostics Market: Overview 

A collection of various diseases caused due to the prevalence of several genetic malfunctions is known as cancer. Cancer is triggered by the uncontrolled growth of several tissues and organs. A human body can be affected by more than 100 types of cancer and each one of them is categorizes on the basis of the cell type that gets affected initially. When the damaged cells split irrepressibly to form tissue lumps and masses, it is when patients suffering from cancer are harmed more. These masses are known as tumors. These tumors can grow easily and interfere with the working of the circulatory, digestive, and nervous systems. Tumors are known for releasing hormones that alter the functions of the body. The tumors that are stable and stay at one spot are benign tumors and the ones that grow are malignant tumors, thus becoming fatal to the human body. 

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4739

The research report presents an in-depth analysis of the historical growth trajectory, current state, and future growth prospects of the global in-vitro cancer diagnostics market. It also evaluates the factors that are likely to positively or adversely impact the growth of the market along with the trends predominant in the market. The important elements at play are also mentioned in the study. Porter’s five forces have also been analyzed to present a clear understanding of the global in-vitro cancer diagnostics market and provide information on the degree of entry and exit barriers in the market. The shares, products, and strategies of the leading players have also been highlighted in the report. 

Global In-vitro Cancer Diagnostics Market: Trends and Opportunities 

In-vitro cancer diagnostics is a technique in which the reagents and medical devices are employed to examine specimens such as body fluids, tissues, stool, urine, and blood. These specimens are derived from the human body to diagnose and detect infections, conditions, and diseases. These tests can be performed in point of care units, hospital based laboratory, and stand-alone laboratories. Researchers and doctors are being impelled to focus on personalized medicines from the conventional diagnostic methods owing to the continuous innovations in the technology and design of in-vitro cancer diagnostics products. 

The rising demand for in-vitro cancer diagnostics arises due to the growing cases of infectious and chronic diseases and the burgeoning geriatric population which is prone to immunological syndromes. Furthermore, the global market for in-vitro cancer diagnostics is also expected to be driven by the extensive spread of knowledge related to rare diseases and the rising application of personalized medications. Likewise, the growing incidences of gynecological diseases, neurological disorders, and colorectal cancer is also expected to propel the demand for in-vitro cancer diagnostics market. The manufacturers operating in the market are likely to gain potential opportunities from the growing disposable income of customers across the globe and the mounting demand for advanced diagnostic equipment. However, the implementation of strict regulations by governments and insufficient reimbursement policies are likely to hamper the growth of the market. 

Global In-vitro Cancer Diagnostics Market: Regional Outlook

Geographically, the global in-vitro cancer diagnostics market is segmented into North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. North America dominated the market over the last couple of years and is expected to retain the lead in the forthcoming years. Asia Pacific is also expected to witness strong growth during the forecast period. 

Companies Mentioned in the Report 

The key players in the market are MDx Health Quest Diagnostics, R-Biopharm AG, Signature Diagnostics, Siemens Healthcare, Randox Laboratories, Epigenomics AG, Beckman Coulter, Inc., and Abbott Laboratories among others. 

Browse Full Research Report on In-vitro Cancer Diagnostics Market:
http://www.transparencymarketresearch.com/in-vitro-cancer-diagnostics-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Wednesday 28 December 2016

Hospital Tumor Marker Market - Global Industry Analysis and Forecast - 2023

A new research report by Transparency Market Research (TMR), titled “Tumor Marker Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” provides qualitative and quantitative insights into the market. The report offers a comprehensive overview of the factors impacting the growth of the market. It presents a detailed description of the competitive landscape of the global hospital tumor marker market.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4744

The growth of the global hospital tumor marker market can be primarily attributed to the increasing prevalence of cancer worldwide. Continuous advancements in technology are supporting easy identification of cancer, which is working in the favor of the market. Moreover, the increasing demand for efficient, cost effective, and safer treatments is boosting the adoption of hospital tumor marker. Another factor driving the market is the increasing government support for the development of advanced and efficient diagnosis and treatment tools for malignancy. Furthermore, anticipated technological breakthroughs in the field of multiple tumor market will create numerous growth opportunities for the market. However, the involvement of high cost in hospital tumor marker procedures is restraining the growth of the global market.

Different types of tumor markers are beta-2-microglobulin (B2M), alpha-fetoprotein (AFP), CA15-3, bladder tumor antigen (BTA), CA 125, CA27.29, calcitonin, CA 19-9, chromogranin A, carcinoembryonic antigen (CEA), inhibin, immunoglobulins, human chorionic gonadotropin (HCG), prostatic acid phosphatase (PAP), NMP22, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), prostate-specific antigen (PSA), and soluble mesothelin-related peptides (SMRP). 

On the basis of geography, the global hospital tumor marker market is divided into Latin America, North America, Asia Pacific, Europe, and the Middle East and Africa. North America will continue to dominate the market until the end of 2023, followed by Europe. The dominance of this region can be attributed to the rising geriatric population and high awareness regarding tumor marker diagnosis. Moreover, various leading companies are domiciled in the region, thereby assuring easy penetration and healthy growth rate. The extensive support offered by government for the development of innovative and clinically advanced tools for cancer diagnosis. The rapidly growing population and the rising prevalence of cancer are fuelling the adoption of the global hospital tumor marker market.

The report profiles key players in the market along with their cost and revenue structure, latest developments, and business strategies. The leading players in the global hospital tumor marker market are F. Hoffmann-La Roche Ltd., Radient Pharmaceuticals Corporation, Mackay Life Sciences, Panacea Pharmaceuticals, Epigenomics AG, Targeted Diagnostics & Therapeutics, Siemens Healthcare, Bio-Rad Laboratories Inc., Biomedical Diagnostics, Becton, Dickinson and Company, Applied Genetic Technologies Corporation, and Abbott Laboratories.

Browse Full Research Report on Hospital Tumor Marker Market:
http://www.transparencymarketresearch.com/hospital-tumor-marker-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Mobile Applications for Melanoma Detection Market Impact Analysis of Opportunities

With the presence of a large pool of mobile applications vendors for melanoma detection, the Europe and Israel market for mobile applications for melanoma detection demonstrates a highly fragmented structure, finds a report by Transparency Market Research (TMR). The competition within the market is exceptionally high as players are constantly engaged in product innovation and advancements in current offerings.

Over the forthcoming years, the leading players, namely, Dr. Mole, Spot Mole, and Melanoma Watch, are expected to shift their focus towards mergers, acquisitions, and partnerships in order to minimize the competition and improve their visibility.

As per the research study, the market for mobile applications for melanoma detection in Europe is likely to progress at an exponential CAGR of 47.0% and reach US$1.4 mn by the end of the forecast period. On the other hand, the market for mobile applications for melanoma detection in Israel will register a strong rise at a remarkable CAGR of 61.20% over the period of the forecast.


Greece to Emerge Leading Market for Mobile Applications for Melanoma Detection in Europe

The research report also offers an analysis based on the geographical segmentation of the Europe and Israel market for mobile applications for melanoma detection. The market in Europe has been segmented into Greece and the Rest of Europe while the market in Israel has been studied separately.
Due to the rise in the number of melanoma cases over the last few years, the market for mobile applications for melanoma detection in Greece has witnessed a robust growth despite the economic volatility. Apart from this, the growing penetration of smartphones has also been adding to the progress of the Greece market for mobile applications for melanoma detection. In the Rest of Europe, Sweden, the U.K., Norway, Switzerland, Denmark, and the Netherlands have been driving the demand for mobile applications for melanoma detection, on account of the high incidence rate of melanoma, and the trend is likely to continue over the forthcoming years.

On the similar lines, Israel has also reported a significant rise in the market for mobile applications for melanoma detection due to the growing prevalence of melanoma and the increasing user base of smartphones. Further, the rising preference for mHealth tools among customers in this country is likely to reflect positively on the demand for mobile applications for melanoma detection over the next few years, notes the market study.

Rising Incidence of Melanoma and Skin Cancer to Impact Europe and Israel Market for Mobile Applications for Melanoma Detection Greatly

“The augmenting incidence of melanoma and skin cancer has been influencing the demand for mobile applications for melanoma detection in Europe and Israel,” states the author of this study. The North and West European countries are more severely affected by melanoma in comparison with the East European nations, which as a result, is leading to a rather high demand for mobile applications for melanoma detection in this part of the region.

The growing trend of mHealth, boosted by the increased penetration of Internet and smartphones, is another key factor behind the growth of the market for mobile applications for melanoma detection in Europe and Israel, reports the research study.

With the significant advancement in mHealth technologies, researchers expect this trend to continue to drive this market over the next few years. However, the rising concerns over the accuracy of the detection test and the high cost of regulation processes may limit the adoption of mobile applications for melanoma detection in Europe and Israel to some extent in the near future, states the report.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Mobile Applications for Melanoma Detection Market - Europe and Israel Industry Analysis, Size, Share, Growth, Trends and Forecast 2014–2022.”

Browse Full Research Report on Mobile Applications for Melanoma Detection Market:
http://www.transparencymarketresearch.com/mobile-applications-melanoma-detection-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Market Segmentation: Implantable Drug Delivery Devices Market by Product 2024

Implantable Drug Delivery Devices Market: Overview  

The global implantable drug delivery devices market is one of the fastest growing markets in the global medical devices industry. Implantable drug delivery devices have already achieved a reasonable edge over many other drug delivery devices. The demand for implantable drug delivery devices such as implantable infusion pumps, contraceptive implants, bio-absorbable stents, intraocular drug delivery implants, and brachytherapy seeds is expected to increase in many emerging nations. The demand for non-biodegradable and biodegradable drug delivery devices is expected to increase, which is another factor predicted to propel the global market.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=887

The report on the global implantable drug delivery devices market uses industry-standard tools such as SWOT analysis and Porter’s five force analysis to measure the important factors driving and restricting the market. Key companies operating in the global market are also listed in the report by the analysts. Key developments in the market and the innovative implantable drug delivery devices introduced by key companies are listed in the report. For a detailed competitive analysis, the global market is divided into segments and sub-segments. Analysts have also focused on the factors that could create new opportunities in the market for the startups.

Implantable Drug Delivery Devices Market: Trends and Opportunities

The global implantable drug delivery devices market is predicted to reach US$21.1 bn by 2018, expected to exhibit an 8.80% CAGR from 2012 to 2018. The occurrence of cardiovascular diseases is rising, which has led to the rising demand for implantable drug delivery devices. The increasing number of interventional cardiologist will also boost the demand for implantable drug delivery devices. The demand for minimally invasive procedures is expected to increase, which will further propel the global market.

However, the rising number of product recalls, the introduction of internet product substitutes and the increasing lawsuits will restrict the growth of the global implantable drug delivery devices market. Stringent government rules and approval norms from FDA are likely to plan an important role in the global market. The implementation of the Affordable healthcare for America Act, 2010 is another factor anticipated to restrict the global market. Although the market is expected to be affected by a few factors, the introduction of new implantable drug delivery devices will benefit the key companies to maintain their dominance.

Implantable Drug Delivery Devices Market: Region-wise Outlook

Based on region, the global implantable drug delivery devices market is divided into Asia Pacific, North America, Europe, and Rest of the World. In 2011, the global market for implantable drug delivery devices was dominated by North America. The application of implantable drug delivery devices in cardiovascular disorders, ophthalmology, birth control, and oncology is rising in North America. This is predicted to help the North America market to maintain its dominance in the global market in the years to come. 

However, going forward, the Asia Pacific market is predicted to be the most promising markets for implantable drug delivery devices owing to the significant growth of emerging nations such as India and China.

Key Players mentioned in the Report:

Some of the leading companies operating in the global implantable drug delivery devices market are Allergan Inc, Medtronic Inc., Merck, Boston Scientific Corporation, Bausch and Lomb Inc., Bayer HealthCare, Nucletron, pSivida Corp., and Abbott Laboratories. With many new implantable drug delivery devices being in the pipeline, the key companies are aiming to maintain their dominance in the global market.

Browse Full Research Report on Implantable Drug Delivery Devices Market
http://www.transparencymarketresearch.com/implantable-drug-delivery-devices.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Renal Denervation Devices Market to Reach a value of US$1.9 Billion by 2021

The study comprises of a strategic analysis of the global market for renal denervation devices, and growth forecast for the period from 2012 – 2021. The scope of the report includes competitive analysis of various market segments based on the product, technology and in-depth scrutiny for different regional markets such as North America, Europe, Asia-Pacific and the rest of the world. The Porter’s Five Forces analysis included in the report provides an insight into market dynamics and industry competition. The report also offers a PESTLE analysis on the market segments with regards to the future, segregated in different chapters. The report details across from 2012 to 2021 which includes the information of all projected activities in every phase of the report. The market forecast has been separated in three groups of years (2012-2015, 2015-2018 and 2018-2021) to include a separate analysis of each group. The unique analysis in this way covers all current and predicted future activities though this period and highlights key milestones in the progress of this market in the coming years. 

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=400

This report provides complete insights on the RDN devices market and also analyzes various factors responsible for market growth. These factors determine various existing trends and their impact on market growth. In all, the report includes a holistic analysis of the global renal denervation devices market, and provides an estimate of growth for the period 2012 – 2021, keeping in mind the various factors affecting the market. 

This report also analyzes current trends for hypertension treatment methods and advantages of renal denervation systems over other methods which act as a catalyst for the growth in the market. The report provides analysis of the most popular RDN device platforms such as Medtronic’s Symplicity, Covidien’s OneShot, Boston Scientific’s (Vessix Vascular) V2 system, and other emerging devices which will enable stakeholders to map their strategies. 

The report also analyzes growth strategies implemented by existing players which will guide emerging players to develop their own strategies and helps existing players to structure their planning process. The report also includes entry barriers to be considered to cater to the exact business opportunities in this market. Additionally, to aid in tactical decision making, the report also includes competitive profiling of leading players, recent developments in the industry and various business strategies adopted by them. This report will help manufacturers, suppliers and distributors in the renal denervation field to plan and implement their roadmap in different market areas such as emerging geographies and new technologies.

1.2 Renal Denervation Devices: Market Segmentation

The study segments the market by technologies used for denervation such as Radiofrequency, Ultrasound, Micro-infusion of drugs (Chemical) and radiation. The report also segments the market according to the brand of products available in the market, particularly, Symplicity, EnligHTN, OneShot, V2 and others. Finally the report has given an in-depth analysis of the epidemiology, growth drivers and restraints by geography in the final section.

Browse Full Research Report on Renal Denervation Devices Market:
http://www.transparencymarketresearch.com/renal-denervation-devices-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Tuesday 27 December 2016

Global Imaging Biomarkers Market Outlook by Product & Application - 2023

The global market for imaging biomarker is the focus of analysis of a recent market research report by Transparency Market Research. The detailed report examines the present state of the market and presents a thorough forecast regarding the growth prospects of the key market segments and regional markets. The report is titled “Imaging Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015–2023.”

The market is chiefly driven by the rising prevalence of a variety of cancers across the globe. Biomarkers are known to be of great help in the early detection of cancer, leading to a promising rise in rate of survival among patients. The American Cancer Society states that by 2030, the number of cancer cases will rise to nearly 21.4 mn by 2030. 13.2 mn deaths will result directly from cancer and related complications by the said year.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2381

This scenario will lead to a significant rise in demand for technologies that can provide key insights into the cancer etiology and can effectively diagnose, detect, and treat cancer. As a result, the market for imaging biomarkers will gain significant impetus in the near future due to the key role played by imaging biomarkers in the detection of cancer.

For the report, the global imaging biomarkers market has been segmented based on criteria such as application, imaging technology, and geography. In terms of imaging technologies, the report examines segments such as computed tomography (CT), positron emission tomography (PET), ultrasound, and magnetic resonance imaging (MRI). 

Geographically, the global imaging biomarkers market is dominated by developed regions such as North America and Europe. The well-established and technologically healthcare infrastructure in these regions is the key factor fueling the growth of the imaging biomarkers market. Thanks to extensive investments poured in for R&D activities, the markets for imaging biomarkers across these regions are expected to exhibit strong growth over the forecast period as well.

Nevertheless, the market is expected to exhibit the most promising growth in Asia Pacific over the forecast period. Factors such as improvement in the healthcare infrastructure, rising expenditure on health and wellness, and rising awareness regarding the importance of regular health checkups among the masses will be the key factors aiding the growth of the Asia Pacific imaging biomarkers market in the next few years.

The vendor landscape of the global imaging biomarkers market features the presence of a large number of regional and international players. Some of the key vendors in the market are Abbott Laboratories, Affymetrix Inc., Agilent Technologies Inc., Becton, Dickinson and Company, Gen-Probe Inc., Biocrates Life Sciences AG, Danaher Corporation, DiagnoCure, Inc., F. Hoffmann La Roche Ltd., Qiagen NV, and Siemens Healthcare.

Browse Full Research Report on Imaging Biomarkers Market:
http://www.transparencymarketresearch.com/imaging-biomarkers-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Monday 26 December 2016

North America Ventricular Assist Device Market Analysis and Forecast, By Product Type 2024

North America Ventricular Assist Device Market: Snapshot

Of late, the market for ventricular assist devices (VADs) is witnessing an exceptional rise in North America on account of the increasing incidence of cardiac arrest and heart failure in various economies in this region, specifically in the U.S. and Canada. The escalating pool of heart patients, boosted by the growing base of the geriatric and the obese population, is having the most prominent impact on the augmenting demand for VADs in this region and is likely to continue to influence this market in the coming years.

As per Transparency Market Research (TMR), the North America market for ventricular assist devices offered an opportunity worth US$0.49 bn in 2015. Expanding at an impressive CAGR of 9.20% during the period from 2016 to 2024, the market is projected to reach US$1.07 bn by 2024.


LVADs to Continue Witnessing Strong Demand

Right ventricular assist devices (RVADs), left ventricular assist devices (LAVDs), bi-ventricular assist devices (Bi-VADs), and total artificial hearts (TAHs) are the main products available in the North America VAD market.

LVADs have been witnessing a higher demand than other devices used for ventricular assistance across the world. This scenario is likely to remain the same in the near future with the opportunity for LVADs in North America rising at a CAGR of 9.60% between 2016 and 2024. TAHs are also expected to experience a significant surge in their demand over the forthcoming years due to their augmenting popularity as one of the most efficient devices used in destination therapy and bridge to transplant.

Increase in Clinical Trials and Awareness Initiatives to Ensure Dominance of the U.S.

The prime domestic markets for ventricular assist devices in North America are U.S. and Canada. With a contribution of US$446 mn, the U.S. surfaced as the key contributor to the overall market in 2015. Researchers predict this domestic market to continue to lead throughout the forecast period, thanks to the significant increase in clinical studies, awareness initiatives, and patient assistance.

On the other hand, Canada, which accounts for a smaller share of the overall market, is poised to witness a sturdy rise and create substantial opportunities for the market’s growth in this region over the next few years. The increasing prevalence of cardiovascular disorders among people and the presence of a favorable reimbursement scenario are likely to fuel the usage of VADs for the treatment of cardiac arrest, heart failure, and other cardiovascular disorders in the years to come, leading to substantial growth of VAD market in Canada. In addition, the low level of competition between players is anticipated to boost the interest of multinational participants in the Canada VAD market in the near future.

The North America VAD market demonstrates a highly competitive landscape due to the intense rivalry between the leading players, namely, Berlin Heart GmbH, SynCardia Systems LLC, Sunshine Heart Inc., St. Jude Medical, Heart Ware International Inc., and Abiomed. Hitherto, they relied upon product innovation for business development; however, their focus is likely to shift towards strategic alliances with new entrants to minimize the competition within the market.

Browse Full Research Report on Ventricular Assist Device Market:
http://www.transparencymarketresearch.com/north-america-ventricular-assist-device-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Advanced Wound Care Management Market to US$11,161.6 Million by 2024

Global Advanced Wound Care Management Market: Snapshot

Rising prevalence of chronic wounds, technological advancements, increasing patient awareness and health care expenditure, and the rapidly rising global population of geriatrics are some of the key factors driving the increased demand for effective measures for wound care management. The growing understanding of the need for treatment of complex wounds is also a key driver of the market. Compared to the traditional wound care products, advanced wound care products are specially designed for the treatment of more complex wounds and have demonstrated their capability in speeding the process of wound healing and recovery. Thus, majority of hospitals have shifted preference toward advanced wound care products.

Transparency Market Research estimates that the global advanced wound care management market will exhibit a 6.3% CAGR from 2016 through 2024, to reach US$11.2 bn by 2024.


Advanced Wound Care Dressings Gain Dominant Share among Key Product Varieties

Based on type of product, advanced wound care dressings was the largest segment of the global advanced wound care management market, accounting for share of 62.4% in the market in 2015. The segment is expected to expand at a CAGR of 6.1% from 2016 to 2024. The market is primarily driven by rising risk factor rates and the need for cost-efficient treatments. The foam dressings segment held the major share of the advanced wound care dressings market in 2015. High flexibility and effectiveness of foam dressings have ensured significant support from medical practitioners and consumers alike. Due to their cost effectiveness, alginate dressings have steadily gained popularity over the past few years.

However, the segment of advanced wound care dressings is expected to lose to the segment of active wound care in terms of rate of growth over the forecast period. Although the active wound care segment will continue to account for a relatively lower share in the market, it will exhibit a CAGR of 8.0% from 2016 through 2024. Companies operational in the segment will, therefore, witness highly lucrative growth opportunities and will be able to strengthen hold on the market over the said period. The segment of antimicrobial dressings will grow at a sluggish pace over the forecast period because these dressings are primarily used to treat infected wounds rather than preventing infection.

North America and Europe to Continue to Dominate Global Market

North America leads the overall advanced wound care market, followed by Europe. These regions are expected to remain the dominant contributors to the global market’s revenue throughout the forecast period as well. The wound dressings market in North America will be driven by growth opportunities such as introduction of wound care diagnostics to identify microorganisms and pathogens and the rapidly developing advanced wound care products segment. Owing to the rising number of patients with diabetes and other vascular diseases, the demand for advanced wound care products has continued to increase across all countries in North America.

The Europe advanced wound care market will be chiefly drive by new product launches in fields such as foam dressings. Rise in the geriatric population, encouraging government initiatives and policies, approval of advanced and more effective products, and rising incidence of diabetes are also driving the Europe advanced wound care market.

The Asia Pacific advanced wound care market is, however, the most attractive regional market in terms of market investment and opportunities. The key factors driving the growth of the advanced wound care management market in Asia Pacific include increase in the geriatric population and the number of patients suffering from chronic diseases. Furthermore, the increased adoption of better quality wound care management products by health care professionals and favorable government reimbursement policies will also support the development of the wound dressings market in Asia Pacific in the near future.

Some of the key players in the advanced wound care management market are 3M, Acelity L.P. Inc., B. Braun Melsungen AG, BSN medical GmbH, Coloplast A/S, ConvaTec Inc., Medline Industries, Inc., Medtronic, Molnlycke Health Care, Organogenesis, Inc., and Smith & Nephew plc.

Browse Full Research Report on Advanced Wound Care Management Market:
http://www.transparencymarketresearch.com/advanced-wound-care-management-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Friday 23 December 2016

Scleroderma Diagnostics and Therapeutics Market High Unmet Medical Needs Propel Growth

Global Scleroderma Diagnostics and Therapeutics Market: Snapshot

The scleroderma therapeutics and diagnostics market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to the increasing focus globally on treatment of orphan diseases. The lack of approved drugs in the market makes it a highly opportune condition for players to convert their innovative drug ideas into successful treatment methods for this rare chronic inflammatory disease.

According to Transparency Market Research, the global scleroderma diagnostics and therapeutics market was valued at US$1,633.5 mn in 2015 and is projected to expand at a CAGR of 9.7% from 2016 to 2024 to reach US$3,663.7 mn by 2024.


Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market, the treatment of scleroderma is challenging for a physician, since no two patients are alike in the progress of their disease. Thus, a host of different drugs are prescribed to every patient, depending on the extent, severity and nature of their symptoms.

It has been observed that patient consumption patterns in the global scleroderma diagnostics and therapeutics market are inclined towards immunosuppressive agents, which have shown to provide relief against several symptoms in both systemic and localized scleroderma cases. Moreover, of the very few treatments identified to efficaciously modify the course of scleroderma, physicians often recommend immunosuppressive agents to manage the most common symptoms of the disease. The segment, as a result, accounts for the dominant share in the global market.

Prostacyclin analogues have been found to have a potent effect in treating systemic scleroderma patients who suffer from pulmonary arterial hypertension. However, these drugs are expensive and thus, even though a smaller sub-set of patients is administered with these agents, their market value is high. This segment grabbed over 8.0% share of the global scleroderma therapeutics market in 2015, and is anticipated to slightly decline by 2024 owing to availability of cheaper alternatives within this segment.

Developed Regions to Continue to Command Dominance

Owing to better diagnostic and treatment rates, in part due to proactive awareness-raising initiatives by various foundations, have aided North America and Europe gain the predominant share in the global scleroderma diagnostics and therapeutics market. North America accounted for a share of nearly 34.0% while Europe held nearly 30% of the global scleroderma therapeutics market in 2015. This is attributed to presence of renowned pharmaceutical companies, research organizations, and institutes in the regions, which are focused on finding a standard treatment for the condition.

The North America and Europe markets for scleroderma diagnostics and therapeutics are expected to retain their dominance in the global scleroderma diagnostics and therapeutics market throughout the forecast period, exhibiting CAGRs of 11.2% and 10.9%, respectively, over the period between 2016 and 2024. The ongoing cutting-edge research pertaining to scleroderma will aid the growth of a niche scleroderma diagnostics and therapeutics market in these regions.

Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2015. The Asia Pacific market will also retain its position in the global market over the forecast period, with factors such as large population and high unmet needs working in favor of market expansion in the region.

Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.

Browse Full Research Report on Scleroderma Diagnostics and Therapeutics Market:
http://www.transparencymarketresearch.com/scleroderma-diagnostics-therapeutics.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Photopheresis Products Market: Rising Prevalence of Cutaneous T-Cell Lymphoma (CTL) to Boost Adoption

As autoimmune disease become increasingly prevalent across the world, researchers are keeping no stone unturned to find the most effective cure. Photopheresis has emerged as one of the most promising treatment options for autoimmune diseases, solid organ transplant rejection, chronic graft versus host diseases, and advanced cutaneous T-cell lymphoma. The treatment was first approved by the FDA in 1988 and is largely considered is the first line of therapy administered in case of aforementioned conditions.  Photopheresis offers a range of benefits such as better efficacy and lesser side effects compared to other drug treatments. While this will create lucrative prospects, the market is also expected to gain from the increasing demand for blood derived products. 

According to Transparency Market Research (TMR), the global photopheresis product market is expected to report a CAGR of 5.9% between 2016 and 2024. At this pace, the market will reach US$371.1 mn by the end of 2024, from a valuation of US$223.1 mn in 2015. 

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14771

Q: How the future of the global photopheresis products market looks like? 

A: Government bodies across the world are encouraging patients to undergo external counter pulsation (ECP) therapy, in the form of favorable reimbursements, for the treatment of various diseases. These policies and the consequent coverage of medical expenses covered under government-supported refunds are encouraging patients towards choosing the therapy for the treatment of various ailments.

Furthermore, globally the incidence of cutaneous T-cell lymphoma (CTL), which is a rare non-Hodgkin lymphoma affecting skin, is increasing. As per the Cutaneous Lymphoma Foundation, every nearly 1500 new cases of (CTL) is reported in the U.S. As the incidence continues to increase, experts are recommending ECP as the first line of therapy despite the availability of various therapies for the treatment of CTL. These factors are indicative of a promising future of the global photopheresis products market. 

Q: Which regions will show most lucrative opportunities for the market? 

Regionally, North America dominates the global photopheresis products market. It held over half of the global market in 2015 and is projected to retain its dominance through the course of the next few years. Favorable reimbursement policies for various disease indications such as CTL and lung transplantation by ECP have been providing significant impetus to the market in North America. For instance, in 2012, Medicare extended their reimbursement coverage for ECP for the treatment of bronchiolitis obliterans syndrome (BOS). Furthermore, various such policies are underway, which are expected to provide boost to the photopheresis products market in North America. 

On the down side, inadequate availability of treatment centers for ECP therapy is likely to slow the pace of gains for the market. Nevertheless, the region boasts comparatively more number of positive factors indicative of a promising future for the market. As per TMR, the North America photopheresis market is expected to show a 5.8% CAGR between 2016 and 2024. 

Meanwhile, the Asia Pacific market which held only 4% of the global photopheresis products market in 2015, is poised to exhibit the leading CAGR of 6.6% during the same forecast period. The visibly increasing investment in the healthcare sectors across the region’s most promising economies has resulted in the rise in number of photopheresis centers in the region. Faster regulatory approvals and emergence of corporate entity in the ECP sector is promoting the growth of the region’s photopheresis products market. 

Browse Full Research Report on Photopheresis Products Market:
http://www.transparencymarketresearch.com/photopheresis-products-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Thursday 22 December 2016

Global Hemostasis Analyzers Market By Technology & Trends 2023

Hemostasis is the study of the processes involved in blood clotting (coagulation). Hematology analyzers, also known as coagulation analyzers, are instruments assisting in treating patients with blood-clotting or bleeding disorders; those with replacement heart valves; and patients who are at high risk of bleeding during surgical procedures. Hematology analyzers work on the principal of flow cytometry based on electrical impedance which aids in identifying the number and size of biological cells. Different types of hematology analyzers include cell counters, coagulators and other hematology apparatus. Flow cytometry labels, lasers and detectors are used in cell counters to differentiate cell populations classified on the basis of known cell surface markers. Increase in demand for quick and accurate results is the driving force for manufacturers to develop newer system capabilities and modern technologies in their hematology analyzers. Provision of broad range testing solutions will assist in outcome of efficient and accurate procedures. The biggest challenge for the vendors is the need to focus on customer concerns and demands along with provision of instruments with higher throughput, efficiency, accuracy and enhanced productivity at lower cost.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1503

Hematology instruments and reagents continue to maintain strong position in healthcare industry. Market players have been observed to invest heavily in product development to offer user-friendly, more sophisticated, efficient and accurate analyzers to meet the demands of hospitals and clinics. Automated systems play a crucial role in transfusion medicines and facilitate screening of blood donors as well as quality control of blood products. The reagents segment continues to lead the market, especially in the Asian countries. The key market players in the reagents segment include Beckman Coulter, Mindray, Horiba and Transasia Bio Medical Ltd.

The global hemostasis analyzers market can be segmented based on test type, product type, end-users and geography. Test types include activated partial thromboplastin time, and prothrombin time test. Product type segment comprises fully automated analyzers and semi automated analyzers, in addition to reagents and consumables. Hospitals, clinical testing laboratories, private and academic research institutes and commercial organizations are the end users of the global hematology analyzers market. Geographically, the market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. North America dominates the global hematology analyzers market owing to the rising installed instrument base leading to higher sales of reagents and support services in the U.S. Beckman Coulter remains the market leader for hematology analyzers in the U.S., though its faces continuous competition from Sysmex products. Emerging markets of India, China and Brazil are registering significant growth due to increasing population, rise in healthcare expenditure and higher affordability, economic development and improving technical capabilities by these countries.

Accuracy of hematology analyzers has been enhanced by automation of systems and use of cell surface marker labels. Automated analyzers function by sampling the blood and classifying cell populations by quantification and description. This may be carried out using both electrical and optical techniques. Sophisticated hematology blood cell analyzers are enabling precise disease diagnosis at an early stage. Fully-automated systems compacted in size, easy to use, providing networking solutions and efficient data management has been the latest drift in opting for hematology analyzers. Continuous technological advancements in molecular diagnostics, lasers, monoclonal antibodies and information technology, coupled with increase in understanding of involvement of immune system in regulating systemic diseases, is expected to have an insightful impact on hematology analyzers market by the end of forecast period. Moreover, advancements in software may help in reduction of instrument manufacturing cost, and allow development of auto-calibration, innovative self-troubleshooting, and other such advanced features.

Abbott, Inc., Agilent Technologies, Beckman Coulter, Inc., Drew Scientific, Inc. Grifols SA, Horiba, Ltd., Roche Diagnostics, Siemens Healthcare, Sysmex Corporation, Hemosonics LLC, and Mindray Corporation are some of the key players in the global hemostasis analyzers market.

Browse Full Research Report on Hemostasis Analyzers Market:
http://www.transparencymarketresearch.com/hemostasis-diagnostics-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Wednesday 21 December 2016

Intravenous Immunoglobulin (IVIG) Market: Rising Patient Pool of Neurological Disorders to Boost Global Consumption of IVIG Products

Global Intravenous Immunoglobulin (IVIG) Market: Snapshot

The global market for intravenous immunoglobulin (IVIG) products and therapies is heading in a positive direction due to several innovative techniques and advantages it offers to clinicians worldwide. The market is expected to expand at a healthy pace in the near future. Factors that will support market’s growth include technological improvements in the methods used for production and purification of IVIG products and an improving health care infrastructure across the globe. The rising patient pool suffering from immunological and neurological disorders, mounting geriatric population, and rising production of IVIG products are also expected to have a significant positive impact on market’s future growth prospects.

Transparency Market Research estimates that the market will exhibit a healthy 8.5% CAGR over the period between 2016 and 2024. Expanding at this pace, the market, which valued at US$7.23 bn in 2015, is expected to reach US$14.92 bn in 2024. 

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930

Hospitals to Retain Dominance but Lose Promise to Home Care

In terms of end users of IVIG infusion therapy and products, the global IVIG market is segmented into hospitals, clinics, and home care settings. Of these, the hospitals segment is presently the dominant end user of the intravenous immunoglobulin (IVIG) market. A continuous rise in the number of patients opting for hospitals rather than clinics is the major driver of the hospitals segment. High budgetary expenditure, rising government investment, and better reimbursement policies also augment the number of patients opting hospitals for intravenous immunoglobulin (IVIG) therapies. 

IVIG infusion therapy is a time consuming procedure, in which the infusion takes place at a slow rate and lasts for a long period of time. This factor is also expected to increase consumer preference to home care settings for treatment. Although the hospitals segment will continue to lead the global IVIG market, the rising inclination to home care is expected to make home care the most lucrative end-user segment of the intravenous immunoglobulin (IVIG) market over the forecast. 

Market in North America to Continue to Remain Highly Lucrative

North America is presently the dominant regional market for intravenous immunoglobulin (IVIG) and is likely to witness significant growth during the forecast period as well. In the U.S., North America’s most lucrative IVIG market, the demand for IVIG infusion therapy is driven by the country’s strong economy, advancements in technology, abundant plasma supply, and rising prevalence of immunological disorders. Other factors ascribable to market growth include the favorable reimbursement policies, high investments in research and development, and increasing geriatric population in the country.

FDA’s approval for payments to plasma donors to encourage plasma donation and boost yield is another major factor driving the IVIG market in the U.S. This has helped the country to not only become self-sufficient in plasma supply, but also a major exporter of plasma derived products globally, consecutively strengthening the North America market.

The IVIG market in Europe is also witnessing strong growth owing to increasing patient pool and geriatric population. Higher acceptance of innovative technologies and launch of new products in the region are also driving the IVIG market. Additionally, the ongoing clinical development of new products is anticipated to boost market growth during the forecast period. Asia Pacific is expected to be a promising market for intravenous immunoglobulin (IVIG) due to developing economies and presence of large underserved patient population. The number of patients suffering from immunological diseases is also high in the region, naturally increasing the demand for intravenous immunoglobulin products and therapies.

Some of the key vendors operating in the highly consolidated global IVIG market are Baxalta Incorporated, Biotest AG, CSL Behring LLC, China Biologic Products, Inc., Grifols S.A., LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, and Sanquin Plasma Products B.V.

Browse Full Research Report on Intravenous Immunoglobulin Market:
http://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Biologics Market: Highly Profitable Returns through Premium Prices to Drive Increased Investments

Global Biologics Market: Snapshot

The global pharmaceutical industry has charted growth at an impressive rate in the past few years owing to a vast increase in research and developmental activities, development and launch of new product varieties, breakthrough progress in treatment options for chronic and rare diseases. A significant rise in big pharmaceutical companies’ operational setups and funds directed towards novel and more effective drug varieties for complex diseases has also been observed across the globe in the past few years. The scenario has led to an increased focus on the development of biologics and a large number of international players are venturing into the global biologics market.

Transparency Market Research estimates that the market will tread along a healthy growth path in the next few years. The market is anticipated to exhibit a CAGR of about 10.9% over the period between 2016 and 2024. If the number holds true, the market is expected to rise to a valuation of US$479, 752 mn by 2024.


Monoclonal Antibodies to Remain Most Profitable Product Variety

The global biologics market is segmented on the basis of product type into monoclonal antibodies, vaccines, recombinant hormones/vaccines, cell therapy, gene therapy and other products. Monoclonal antibodies segment is anticipated to dominate the market throughout the forecast period; the segment is expected to stand for an annual share of 46% by 2024 and expand at a favorable 11.9% CAGR over the period between 2016 and 2024.

The segments of vaccines and recombinant hormones/proteins are also expected to attractive for manufacturers, although growth of these segments will be relatively stationary over the forecast period. The segment of vaccines will exhibit a slight decline by 2024, chiefly owing to the lower pricing of most vaccines and many key contenders on the verge of going off patent in the developed market. The segment of recombinant hormones/proteins will witness a slight rise in its share in the global market by 2024 owing to sustainable sales in developed and emerging markets.

Vast Growth Opportunities in Asia Pacific to Bring in More Investment

Geographically, the global biologics market is segmented into North America, Europe, Latin America, Asia-Pacific, and Middle East and Africa. North America is presently the dominant regional market, holding a share of over 40% in the global market. The region is expected to continue its dominance in terms of revenue contribution to the global market, expected to account for over 40% by 2024 as well.

However, the biologics market in Asia Pacific is expected to emerge as the most attractive regional market, exhibiting a massive 15.6% CAGR from 2016 through 2024. By the end of the forecast period, the region is expected to replace Europe and become the second most profitable region for biologics.

Owing to the presence of an enormous patient-base and low costs of raw material and manufacturing, an increased number of multi-national pharmaceutical companies are expanding their manufacturing and sales capacities in Asia Pacific. Changes in the regulatory scenario in Asia Pacific are also expected to attract many foreign investors in the Asian markets in the next few years. As a result, the biologics market in Asia Pacific is expected to witness highly positive growth in the next few years.

The highly fragmented global market for biologics features the presence of a large number of international pharmaceutical companies and many domestic players. Some of the key vendors in the market are AstraZeneca, AbbVie Inc., Amgen Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Novartis AG, and Sanofi.

Browse Full Research Report on Biologics Market:
http://www.transparencymarketresearch.com/global-biologics-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.